With a handful of medications and dispensary options to choose from, one could argue that medical cannabis, in its current form, is a misnomer to some degree. However, evidence-based decisions relying on small lab samples and anecdotal findings can only carry medical cannabis so far. As medical cannabis markets advance and mature, a lack of data is growing from a gap to a chasm. However, without substantial regulatory changes on the federal level, a lack of U.S. research will continue to hamper the progress of the country’s medical cannabis market. With the approved options treating just a few conditions, most patients remain without a legal medical cannabis option that has gone through FDA trials.
There is no disputing that cannabis provides medicinal relief to scores of people. However, federal regulations limit the scope of testing for marijuana recommended for patients, unlike the rigorous testing standards held for other medicines. As such, only a few cannabis-esque medicines have been able to reach the U.S. market to date. With a handful of medications and dispensary options to choose from, one could argue that medical cannabis, in its current form, is a misnomer to some degree.
Moreover, a lack of conclusive data prevents the community from fully understanding the functions of the plant itself. Without proper insights, medical professionals...
Read the full article @ High Times